Table 1.
Socio-demographic, clinical, and tumor-specific characteristics associated with interval between diagnosis and treatment initiation of ≥ 30 days
| Factor | Interval of 0 to 29 days | Interval of > 30 days | p-valuea) |
|---|---|---|---|
| Total (n=1,702) | 1,133 (66.6) | 569 (33.4) | |
| Age (yr) | |||
| ≤ 39 | 180 (15.9) | 74 (13.0) | 0.336 |
| 40-49 | 478 (42.2) | 241 (42.4) | |
| 50-59 | 320 (28.2) | 160 (28.1) | |
| 60-69 | 124 (10.9) | 78 (13.7) | |
| ≥ 70 | 31 (2.7) | 16 (2.8) | |
| Address | |||
| Seoul-Incheon area | 795 (70.2) | 398 (69.9) | 0.925 |
| Outside of capital area | 338 (29.8) | 171 (30.1) | |
| Place of diagnosis | |||
| SNUH | 494 (43.6) | 195 (34.3) | < 0.001 |
| Other hospital | 639 (56.4) | 374 (65.7) | |
| Education | |||
| ≤ High school | 636 (56.1) | 350 (61.5) | 0.091 |
| > High school | 443 (39.1) | 92 (33.7) | |
| Unknown | 54 (4.8) | 27 (4.7) | |
| Marital status | |||
| Married | 1,033 (91.2) | 516 (90.7) | 0.621 |
| Single | 60 (5.3) | 38 (6.7) | |
| Divorced | 9 (0.8) | 3 (0.5) | |
| Widowed | 7(0.6) | 4 (0.7) | |
| Unknown | 24 (2.1) | 8 (1.4) | |
| Comorbidity | |||
| Other than cancer | 306 (27.0) | 186 (32.7) | 0.015 |
| No comorbidities | 827 (73.0) | 383 (67.3) | |
| Symptom | |||
| Yes | 761 (67.2) | 362 (63.6) | 0.155 |
| No | 369 (32.6) | 207 (36.4) | |
| Unknown | 3 (0.3) | 0| | |
| Cancer family history | |||
| Breast cancer related | 101 (8.9) | 43 (7.5) | 0.609 |
| Not related to breast cancer | 173 (15.3) | 85 (14.9) | |
| No cancer family history | 859 (75.8) | 441 (77.5) | |
| Additional biopsy | |||
| Any | 36 (3.2) | 62 (10.9) | < 0.001 |
| None | 1,097 (96.8) | 507 (89.1) | |
| Imaging before admission | |||
| Any | 424 (37.4) | 340 (59.8) | < 0.001 |
| None | 709 (62.6) | 229 (40.2) | |
| Not routine imaging before admission | |||
| Any | 5 (0.4) | 27 (4.7) | < 0.001 |
| None | 1,128 (99.6) | 542 (95.3) | |
| Hospitalization | |||
| Any | 2 (0.2) | 11 (1.9) | < 0.001 |
| None | 1,131 (99.8) | 558 (98.1) | |
| Consultation | |||
| Any | 48 (4.2) | 56 (9.8) | < 0.001 |
| None | 1,085 (95.8) | 513 (90.2) | |
| Immediate reconstruction | |||
| Yes | 11 (1.0) | 6 (1.1) | 0.870 |
| No | 1,122 (99.0) | 563 (98.9) | |
| Clinical stage at diagnosis | |||
| Diagnosis by FNA | 29 (2.6) | 14 (2.5) | 0.109 |
| In situ cancer | 91 (8.0) | 59 (10.4) | |
| T1N0 | 681 (60.1) | 357 (62.7) | |
| ≥ T2 or LN(+) | 332 (29.3) | 139 (24.4) | |
| Pathological stage | |||
| T size ≤ 2 cm | 625 (55.2) | 327 (57.5) | 0.366 |
| T size > 2 cm | 508 (44.8) | 242 (42.5) | |
| No ALN metastasis | 727 (64.2) | 387 (68.0) | 0.115 |
| ALN metastasis | 406 (35.8) | 182 (32.0) | |
| Histologic grade | |||
| Grade 1, 2 | 527 (50.6) | 290 (55.3) | 0.075 |
| Grade 3 | 515 (59.4) | 234 (44.7) | |
| Hormone receptor status | |||
| Positive | 764 (67.4) | 411 (72.2) | 0.043 |
| Negative | 369 (32.6) | 158 (27.8) | |
| Ki-67 | |||
| Low (< 10%) | 892 (78.9) | 452 (79.7) | 0.709 |
| High (≥ 10%) | 238 (21.1) | 115 (20.3) | |
| Radiotherapy | |||
| Yes | 761 (67.2) | 385 (67.7) | 0.837 |
| No | 372 (32.8) | 184 (32.3) | |
| Chemotherapy | |||
| Yes | 869 (76.7) | 400 (70.3) | 0.004 |
| No | 264 (23.3) | 169 (29.7) | |
| Endocrine therapy | |||
| Yes | 757 (66.8) | 411 (72.2) | 0.023 |
| No | 376 (33.2) | 158 (27.8) |
SNUH, Seoul National University Hospital; FNA, fine needle aspiration; LN, lymph node; ALN, axillary lymph node.
a)
p-values are from chi-square test.